Standout Papers
Citation Impact
Citing Papers
Effective treatment of severe COVID-19 patients with tocilizumab
2020 Standout
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology.
1999
Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
2000
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
2008
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
2009
Open label trial of anakinra in active ankylosing spondylitis over 24 weeks
2004
The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis
2010
Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
2001 Standout
The Complex Immunology of Human Coccidioidomycosis
2007
Considerations with the use of biological therapy in the treatment of rheumatoid arthritis
2004
Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial
2006
Systemic Effects of Chronic Obstructive Pulmonary Disease
2005
Design of effective immunotherapy for human autoimmunity
2005 Nature
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation
2009
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
2008
Inflammation and cancer
2002 StandoutNature
Infections in patients with rheumatoid arthritis treated with biologic agents
2005
Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis
2008
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
2001
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004
2004
A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
1999 Standout
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
2009
Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type
2003
Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis
2006
Adenosine: an endogenous regulator of innate immunity
2003
A randomized, placebo‐controlled, double‐masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis
2005
Rheumatoid arthritis
2016 Standout
Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial
2008
Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis
2006
Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population
2009
Very early treatment with infliximab in addition to methotrexate in early, poor‐prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve‐month randomized, double‐blind, placebo‐controlled trial
2005
Even though T-cell-directed trials have been of limited success, is there reason for optimism?
2006
Pathogenesis and clinical features of psoriasis
2007 Standout
Coccidioidomycosis in Rheumatology Patients
2007
Anti-tumour necrosis factor α therapy in rheumatoid arthritis: an update on safety
2004
Long‐term safety and efficacy of etanercept in children with polyarticular‐course juvenile rheumatoid arthritis
2006
Coccidioidomycosis in Liver Transplant Recipients in an Endemic Area
2010
The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo
2009
Pro-resolving lipid mediators are leads for resolution physiology
2014 StandoutNature
Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point
2015
A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal
2005
Juvenile idiopathic arthritis
2007 Standout
Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
2003
Trial of Tocilizumab in Giant-Cell Arteritis
2017 Standout
Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005
2005
Inflammatory bowel disease: clinical aspects and established and evolving therapies
2007 Standout
Eligibility of patients in routine care for major clinical trials of anti–tumor necrosis factor α agents in rheumatoid arthritis
2003
T cell epitope–specific immune therapy for rheumatic diseases
2005
Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin
2005
Induction of Intestinal Th17 Cells by Segmented Filamentous Bacteria
2009 Standout
Treatment of Multicentric Reticulohistiocytosis With Etanercept
2004
Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial
1999 Standout
Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study
2006
EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
2006
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002)
2002
The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review
2007
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
2013
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept
2008
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion
2002
Influence of anti–tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: Results from the British Society for rheumatology biologics register
2010
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
2009
Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis
2004 Standout
Rheumatoid arthritis in the developing world
2003
Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
2008
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
2005
Tumor Necrosis Factor-α Blockade: A Novel Therapy for Rheumatic Disease
2002
Very low‐dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: A multicenter, double‐blind, placebo‐controlled trial
2005
The Pathogenesis of Rheumatoid Arthritis
2011 Standout
Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: Results of a multicenter, randomized, double‐blind, active drug–controlled study
2008
Nonresolving Inflammation
2010 Standout
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
2009
Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study
2002
Modelling the cost effectiveness of TNF- antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry
2007
Role for TNF in atherosclerosis? Lessons from autoimmune disease
2009
Tumor necrosis factor antagonist mechanisms of action: A comprehensive review
2007
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
2006
Cytokine Pathways and Joint Inflammation in Rheumatoid Arthritis
2001 Standout
Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy
2003
Glutamate neurotoxicity and diseases of the nervous system
1988 Standout
The role of innate mediators in inflammatory response
2002
Prevalence of Joint Disease in Patients with Psoriasis
2003
Management of coccidioidomycosis in patients receiving biologic response modifiers or disease‐modifying antirheumatic drugs
2012
Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation
2002
Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?
2005
Tumor‐Necrosis‐Factor Blockers: Differential Effects on Mycobacterial Immunity
2006
Graves' Ophthalmopathy
2010 Standout
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial
2004
Tumor Necrosis Factor Antagonists: Different Kinetics and/or Mechanisms of Action May Explain Differences in the Risk for Developing Granulomatous Infection
2006
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
2004
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components
1999
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
2000 Standout
Infliximab Maintenance Therapy for Fistulizing Crohn's Disease
2004 Standout
Ankylosing spondylitis
2007 Standout
Inflammatory Bowel Disease
2002 Standout
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
2004
Genes and environment in arthritis: can RA be prevented?
2002
Psoriatic arthritis assessment tools in clinical trials
2005
Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials
2007
Anakinra for Rheumatoid Arthritis: A Systematic Review
2009
Dose escalation of infliximab in clinical practice: improvements seen may be explained by a regression-like effect
2004
A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant‐cell arteritis
2002
Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study
2008
Autoantibody profiling in patients with very early rheumatoid arthritis: a follow-up study
2009
Refractory Disseminated Coccidioidomycosis and Mycobacteriosis in Interferon‐γ Receptor 1 Deficiency
2009
Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
2002 Standout
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling
2011
p21Cip1 Is Required for the Development of Monocytes and Their Response to Serum Transfer-induced Arthritis
2006
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial
2007
Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha
2010
Hematopoietic Stem-Cell Transplantation
2006 Standout
Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis
2004
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison
2006
A Comparison between Enriched and Nonenriched Enrollment Randomized Withdrawal Trials of Opioids for Chronic Noncancer Pain
2011
The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
2005
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trial
2004
Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression
2004
Rheumatic diseases: the effects of inflammation on bone
2005
Cellular and Molecular Mechanisms of Pain
2009 StandoutNobel
Etanercept
2002
Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis
2009
Rheumatoid arthritis
2010 Standout
Review of Eight Pharmacoeconomic Studies of the Value of Biologic DMARDs Adalimumab, Etanercept, and Infliximab) in the Management of Rheumatoid Arthritis
2006
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
2014
Infliximab in active early rheumatoid arthritis
2004
Costimulation Blockade with Belatacept in Renal Transplantation
2005 Standout
Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study
2007
Treatment of early seropositive rheumatoid arthritis: Doxycycline plus methotrexate versus methotrexate alone
2006
The Inflammasomes
2010 Standout
Mechanisms and Functions of Inflammasomes
2014 Standout
Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
2006
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
2009
Therapeutic strategies for rheumatoid arthritis
2003
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double‐blind, placebo‐controlled trial
2002
Coccidioidomycosis-associated Deaths, United States, 1990–2008
2012
The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic-onset juvenile idiopathic arthritis
2008
Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-? antagonists
2007
Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti–tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study
2005
Safety of Tumour Necrosis Factor-?? Antagonists
2004
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
2012
The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis
2010
Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration
2002
Inflammation, Atherosclerosis, and Coronary Artery Disease
2005 Standout
Recurrent miscarriage
2006 Standout
Idiopathic pulmonary fibrosis
2011 Standout
Safety of extended treatment with anakinra in patients with rheumatoid arthritis
2006
Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: A randomized, controlled trial
2003
A paradigm for the evaluation and management of spinal coccidioidomycosis
2015
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis
2004
Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry
2005
Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial
2004
Current management of juvenile idiopathic arthritis
2006
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Systemic effects of chronic obstructive pulmonary disease
2003
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate
2008
Protein therapeutics: a summary and pharmacological classification
2007 Standout
Rheumatoid Arthritis
2008
Rapid responses to anakinra in patients with refractory adult‐onset Still's disease
2005
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Global burden of COPD: risk factors, prevalence, and future trends
2007 Standout
Radiographic outcome after three years of patients with early erosive rheumatoid arthritis treated with intramuscular methotrexate or parenteral gold. Extension of a one‐year double‐blind study in 174 patients
2002
Biologics in development for rheumatoid arthritis: Relevance to osteoarthritis☆
2006
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
2004
JNK1 is not essential for TNF-mediated joint disease
2004
Sympathetic Neural Mechanisms of Cyclosporine-Induced Hypertension*
1996
New Drugs for Rheumatoid Arthritis
2004
Effects of three anti-TNF-α drugs: Etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro
2008
An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients
2010
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
2012 Standout
Autoimmunity and Anti-TNF-α Agents
2005
Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis
2006
Development of Monocytes, Macrophages, and Dendritic Cells
2010 StandoutScience
Adalimumab in the Treatment of Rheumatoid Arthritis
2006
Methotrexate in Rheumatoid Arthritis
1987
Pilot trial of etanercept in the treatment of inclusion-body myositis
2006
2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis
2016 Standout
Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.
2005
Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents
2009
Combination therapy versus monotherapy for the treatment of patients with rheumatoid arthritis.
2000
A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice
2005 StandoutNobel
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Novel TNF antagonists for the treatment of rheumatoid arthritis
2009
CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016
2016 Standout
Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag
2009 StandoutNobel
Gout
2021 Standout
Radiotherapy combination opportunities leveraging immunity for the next oncology practice
2016
The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis.
2006
Methotrexate and histologic hepatic abnormalities: A meta-analysis
1991
Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings
2000 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Disease activity measures for rheumatoid arthritis.
2008
Effects of Febuxostat in Early Gout
2017
Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis
2008
Osteoarthritis: an update with relevance for clinical practice
2011 Standout
Recent Advances in Our Understanding of the Environmental, Epidemiological, Immunological, and Clinical Dimensions of Coccidioidomycosis
2013
Matrix Metalloproteinases: Role In Arthritis
2006
JNK1 controls mast cell degranulation and IL-1β production in inflammatory arthritis
2010 StandoutNobel
Education, self‐care, and outcomes of rheumatic diseases: Further challenges to the “biomedical model” paradigm
1997
Generic quality-of-life assessment in rheumatoid arthritis.
2007
Works of John Tesser being referenced
Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis.
2004
Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty‐eight weeks. An open‐label extension study
1997
Anakinra, a recombinant human interleukin‐1 receptor antagonist (r‐metHuIL‐1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo‐controlled trial
2003
Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis
1995
Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis
2001
Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor α antagonists
2004
A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
2000 Standout
Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)
2020
The safety of anakinra in high‐risk patients with active rheumatoid arthritis: Six‐month observations of patients with comorbid conditions
2004
Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes
2002
The liver in rheumatic diseases
1982
CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis.
2002
Clinical and immunologic effects of a PRIMATIZED anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial.
1998
Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis.
2006
Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial
2001